Bamberger Federführer. Die besten Texte aus drei Jahren Literaturwettbewerb an der Universität Bamberg (2009-2011)

Im Kreise des Redaktions-Teams der studentischen Hochschulgruppe Feki.de entstand im November 2008 die Idee, einen Literaturwettbewerb an der Universität Bamberg zu etablieren. Das Projekt sollte es Studierenden aller Fachrichtungen ermöglichen, literarisch tätig zu werden und sich mit ihren Texten dem Urteil einer Jury bzw. der Leser zu stellen. Insgesamt drei Mal wurde der Wettbewerb durchgeführt: 2009 wurde die beste Kurzgeschichte zum Thema „Um 20 Uhr am Gabelmoo“ gesucht, im Jahr darauf lautete das Thema schlicht „fertig. Der letzte Wettbewerb stand schließlich unter dem Motto „Heimat“. Die Auswahl der Siegertexte übernahm eine Jury, bestehend aus Vertretern verschiedener Hochschulgruppen – Feki.de, Rezensöhnchen und Ottfried –, Prof. Dr. Andrea Bartl, Inhaberin der Professur für Neuere deutsche Literaturwissenschaft, dem Autor und Kritiker Rolf Bernhard Essig sowie wechselnd den Autoren Nora Gomringer, Kurt Kreiler und Nefvel Cumart. Daneben konnten die Feki.de-Leser über den jeweiligen Publikumspreisträger abstimmen. Neben den Studierenden der Universität Bamberg waren ab dem zweiten Jahr auch Teilnehmer der Schreibwerkstatt der JVA Ebrach eingeladen, ihre Texte einzu­senden. Im Vergleich mit den studentischen Texten boten die Beiträge der Gefangenen einen interessanten Perspektivwechsel für alle Teil­nehmer und Leser. Insgesamt 24 Kurzgeschichten aus den Jahren 2009 bis 2011 haben wir in diesem Band zusammengestellt. Neben den jeweiligen Siegertexten finden sich in der Anthologie auch die Beiträge der JVA-Bewohner zum Thema „fertig“, sowie ausgewählte Texte Studierender, die die Podestplätze nur knapp verfehlten

Overexpression of hepatoma-derived growth factor in melanocytes does not lead to oncogenic transformation

<p>Abstract</p> <p>Background</p> <p>HDGF is a growth factor which is overexpressed in a wide range of tumors. Importantly, expression levels were identified as a prognostic marker in some types of cancer such as melanoma.</p> <p>Methods</p> <p>To investigate the presumed oncogenic/transforming capacity of HDGF, we generated transgenic mice overexpressing HDGF in melanocytes. These mice were bred with mice heterozygous for a defective copy of the Ink4a tumor suppressor gene and were exposed to UV light to increase the risk for tumor development both genetically and physiochemically. Mice were analyzed by immunohistochemistry and Western blotting. Furthermore, primary melanocytes were isolated from different strains created.</p> <p>Results</p> <p>Transgenic animals overexpressed HDGF in hair follicle melanocytes. Interestingly, primary melanocytes isolated from transgenic animals were not able to differentiate <it>in vitro </it>whereas cells isolated from wild type and HDGF-deficient animals were. Although, HDGF^-/-/Ink4a^+/-mice displayed an increased number of epidermoid cysts after exposure to UV light, no melanomas or premelanocytic alterations could be detected in this mouse model.</p> <p>Conclusions</p> <p>The results therefore provide no evidence that HDGF has a transforming capacity in tumor development. Our results in combination with previous findings point to a possible role in cell differentiation and suggest that HDGF promotes tumor progression after secondary upregulation and may represent another protein fitting into the concept of non-oncogene addiction of tumor tissue.</p

OHB initiatives in development of additive manufacturing technology for opto-mechanical and mechatronic space systems

Additive Manufacturing (AM) technology has shown impressive new opportunities and convincing results over the last years, mainly in terrestrial applications. Today, it has proven to represent a completely new approach to shape complex mechanical parts, with enormous potential for optimization of dedicated parameters. Numerous possibilities shine up for the aerospace industry, among others, and let engineers dream of mechanical parts which only some years ago looked like science fiction. OHB System has been involved in the development of Additive Manufacturing since more than five years via several ESA studies, DLR-funded projects and by significant internal R&D activities. These projects and studies have convinced us of the potential of AM for future satellite platforms, instruments and payloads. A new dimension of freedom in generating shapes and geometries is opened, offering more flexibility for optimizing the parts and components according to functional and performance requirements. On the other hand, the efforts of qualifying an AM part to flight worthiness are significantly higher than for conventional manufacturing technologies, taking into account all the required aspects of material and production process control, inspection and testing. A concise trade-off has to be performed for each potential use case to find out whether these high efforts and resulting costs are justified by the benefits of the new technology in terms of e.g. light weighting, ease of integration and performance improvement. The paper will introduce the OHB AM roadmap, which has been developed jointly by OHB experts from both sites in Bremen and Oberpfaffenhofen, following in-depth analysis of the potential impact of the technology on space systems. It will furthermore provide an overview of applications where AM is expected to offer extraordinary opportunities. Among these 'high-potential' applications are the two following topics: • opto-mechanical assemblies (isostatic structures, optical mounts) and • mechatronic systems (compliant mechanisms or integrated smart structures). The paper will report on the objectives and work logic of ongoing studies in these specific topics and provide intermediate results

In situ X-ray diffraction environments for high-pressure reactions

© International Union of Crystallography 2015.New sample environments and techniques specifically designed for in situ powder X-ray diffraction studies up to 1000 bar (1 bar = 10&lt;sup&gt;5&lt;/sup&gt; Pa) gas pressure are reported and discussed. The cells can be utilized for multiple purposes in a range of research fields. Specifically, investigations of gas-solid reactions and sample handling under inert conditions are undertaken here. Sample containers allowing the introduction of gas from one or both ends are considered, enabling the possibility of flow-through studies. Various containment materials are evaluated, e.g. capillaries of single-crystal sapphire (Al2O3), quartz glass (SiO2), stainless steel (S316) and glassy carbon (Sigradur K), and burst pressures are calculated and tested for the different tube materials. In these studies, high hydrogen pressure is generated with a metal hydride hydrogen compressor mounted in a closed system, which allows reuse of the hydrogen gas. The advantages and design considerations of the in situ cells are discussed and their usage is illustrated by a case study

<i>In Situ</i> Monitoring of Fast Li-Ion Conductor Li₇P₃S₁₁ Crystallization Inside a Hot-Press Setup

Rechargeable solid-state lithium ion batteries (SSLB) require fast ion conducting solid electrolytes (SEs) to enable high charge and discharge rates. Li₇P₃S₁₁ is a particularly promising lithium solid electrolyte, exhibiting very high room temperature conductivities of up to 17 mS·cm^–1 and high ductility, allowing fast ion transport through the bulk and intimate contact to high surface electrodes. Here we present a novel hot-press setup that facilitates the synthesis of solid electrolytes by combining <i>in situ</i> electrochemical impedance spectroscopy (EIS) with simultaneous temperature- and pressure-monitoring. While a high room temperature conductivity in the order of 10 mS·cm^–1 is readily achieved for phase pure Li₇P₃S₁₁ with this design, it further enables monitoring of the different steps of crystallization from an amorphous Li₂S–P₂S₅ glass to triclinic Li₇P₃S₁₁. Nucleation, crystallization andat temperatures exceeding 280 °Cdecomposition of the material are analyzed in real time, enabling process optimization. The results are supported <i>ex situ</i> by means of X-ray diffraction, X-ray photoelectron spectroscopy, scanning electron microscopy and Raman spectroscopy. Proof-of-principle experiments show the promising cycling- and rate capability of Li_0.3In_0.7/Li₇P₃S₁₁/S-composite all-solid-state batteries. It is furthermore presented that discharging below a limit of 1.2 V results in decomposition of the SE/cathode interface

Intravenous NPA for the treatment of infarcting myocardium early: InTIME-II, a double-blind comparison on of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction

Aims to compare the efficacy and safety of lanoteplase, a single-bolus thrombolytic drug derived from alteplase tissue plasminogen activator, with the established accelerated alteplase regimen in patients presenting within 6 h of onset of ST elevation acute myocardial infarction. Methods and Results 15 078 patients were recruited from 855 hospitals worldwide and randomized in a 2:1 ratio to receive either lanoteplase 120 KU. kg-1 as a single intravenous bolus, or up to 100 mg accelerated alteplase given over 90 min. The primary end-point was all-cause mortality at 30 days and the hypothesis was that the two treatments would be equivalent. By 30 days, 6.61% of alteplase-treated patients and 6.75% lanoteplase-treated patients had died (relative risk 1.02). Total stroke occurred in 1.53% alteplase- and 1.87% lanoteplase-treated patients (ns); haemorrhagic stroke rates were 0.64% alteplase and 1.12% lanoteplase (P=0.004). The net clinical deficit of 30-day death or non-fatal disabling stroke was 7.0% and 7.2%, respectively. By 6 months, 8.8% of alteplase-treated patients and 8.7% of lanoteplase-treated patients had died. Conclusion Single-bolus weight-adjusted lanoteplase is an effective thrombolytic agent, equivalent to alteplase in terms of its impact on survival and with a comparable risk-benefit profile. The single-bolus regimen should shorten symptoms to treatment times and be especially convenient for emergency department or out-of-hospital administration. (C) 2000 The European Society of Cardiology